Clinical trial
Immuno & Safety Study of GSK Biologicals' Thio or Preservative Free Hepatitis B…
NCT00343915 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00343915 |
|---|---|
| Title | Immuno & Safety Study of GSK Biologicals' Thio or Preservative Free Hepatitis B Vaccine in Subjects Aged 11-15 Yrs |
| Official title | Long-term Study of Immune Response Persistence of GSK Biologicals' 2-dose Thiomersal-free Engerix™-B and 3-dose Preservative-free Engerix™-B Vaccines in Subjects Aged 11-15 Yrs |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis B |
| Intervention type | Biological |
| Interventions | Engerix™-B (thiomersal-free) 20µg, 10 μg Engerix™-B (preservative-free), placebo |
| Enrollment | 267 |
| Start date | Apr 21, 2004 |
| Primary completion | Jan 10, 2008 |
| Completion | Jan 10, 2008 |
| First posted | Jun 23, 2006 |
| Last update posted | Jun 10, 2019 |
| Countries | Australia, Belgium, Ukraine |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: